Search Results - "GLEAVE, MARTIN"

Towards precision oncology in advanced prostate cancer by Ku, Sheng-Yu, Gleave, Martin E., Beltran, Himisha

“…Metastatic biopsy programmes combined with advances in genomic sequencing have provided new insights into the molecular landscape of castration-resistant…”
Get full text

Small heat shock proteins in cancer therapy and prognosis by Zoubeidi, Amina, Gleave, Martin

“…Hsp27 and clusterin (CLU are stress-activated small heat shock proteins that are up-regulated in many cancers where they play important roles in stress-induced…”
Get full text

Clinical and molecular features of treatment‐related neuroendocrine prostate cancer by Akamatsu, Shusuke, Inoue, Takahiro, Ogawa, Osamu, Gleave, Martin E

“…Treatment‐related neuroendocrine prostate cancer is a lethal form of prostate cancer that emerges in the later stages of castration‐resistant prostate cancer…”
Get full text

Aggressive Variants of Castration-Resistant Prostate Cancer by BELTRAN, Himisha, TOMLINS, Scott, LOGOTHETIS, Christopher, RUBIN, Mark A, APARICIO, Ana, ARORA, Vivek, RICKMAN, David, AYALA, Gustavo, HUANG, Jiaoti, TRUE, Lawrence, GLEAVE, Martin E, SOULE, Howard

“…A subset of patients with advanced castration-resistant prostate cancer may eventually evolve into an androgen receptor (AR)-independent phenotype, with a…”
Get full text

Targeting the adaptive molecular landscape of castration‐resistant prostate cancer by Wyatt, Alexander W, Gleave, Martin E

“…Castration and androgen receptor (AR) pathway inhibitors induce profound and sustained responses in advanced prostate cancer. However, the inevitable…”
Get full text

Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer by Azad, Arun A, Volik, Stanislav V, Wyatt, Alexander W, Haegert, Anne, Le Bihan, Stephane, Bell, Robert H, Anderson, Shawn A, McConeghy, Brian, Shukin, Robert, Bazov, Jenny, Youngren, Jack, Paris, Pamela, Thomas, George, Small, Eric J, Wang, Yuzhuo, Gleave, Martin E, Collins, Colin C, Chi, Kim N

“…Although novel agents targeting the androgen-androgen receptor (AR) axis have altered the treatment paradigm of metastatic castration-resistant prostate cancer…”
Get full text

Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial by Khalaf, Daniel J, Annala, Matti, Taavitsainen, Sinja, Finch, Daygen L, Oja, Conrad, Vergidis, Joanna, Zulfiqar, Muhammad, Sunderland, Katherine, Azad, Arun A, Kollmannsberger, Christian K, Eigl, Bernhard J, Noonan, Krista, Wadhwa, Deepa, Attwell, Andrew, Keith, Bruce, Ellard, Susan L, Le, Lyly, Gleave, Martin E, Wyatt, Alexander W, Chi, Kim N

“…Abiraterone acetate plus prednisone and enzalutamide are both used for the treatment of metastatic castration-resistant prostate cancer. We aimed to determine…”
Get full text

Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer by Annala, Matti, Vandekerkhove, Gillian, Khalaf, Daniel, Taavitsainen, Sinja, Beja, Kevin, Warner, Evan W, Sunderland, Katherine, Kollmannsberger, Christian, Eigl, Bernhard J, Finch, Daygen, Oja, Conrad D, Vergidis, Joanna, Zulfiqar, Muhammad, Azad, Arun A, Nykter, Matti, Gleave, Martin E, Wyatt, Alexander W, Chi, Kim N

“…Primary resistance to androgen receptor (AR)-directed therapies in metastatic castration-resistant prostate cancer (mCRPC) is poorly understood. We randomized…”
Get more information

The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer by Akamatsu, Shusuke, Wyatt, Alexander W., Lin, Dong, Lysakowski, Summer, Zhang, Fan, Kim, Soojin, Tse, Charan, Wang, Kendric, Mo, Fan, Haegert, Anne, Brahmbhatt, Sonal, Bell, Robert, Adomat, Hans, Kawai, Yoshihisa, Xue, Hui, Dong, Xin, Fazli, Ladan, Tsai, Harrison, Lotan, Tamara L., Kossai, Myriam, Mosquera, Juan Miguel, Rubin, Mark A., Beltran, Himisha, Zoubeidi, Amina, Wang, Yuzhuo, Gleave, Martin E., Collins, Colin C.

“…More potent targeting of the androgen receptor (AR) in advanced prostate cancer is driving an increased incidence of neuroendocrine prostate cancer (NEPC), an…”
Get full text

Deep Docking: A Deep Learning Platform for Augmentation of Structure Based Drug Discovery by Gentile, Francesco, Agrawal, Vibudh, Hsing, Michael, Ton, Anh-Tien, Ban, Fuqiang, Norinder, Ulf, Gleave, Martin E, Cherkasov, Artem

“…Drug discovery is a rigorous process that requires billion dollars of investments and decades of research to bring a molecule “from bench to a bedside”. While…”
Get full text

Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer by Vandekerkhove, Gillian, Struss, Werner J., Annala, Matti, Kallio, Heini M.L., Khalaf, Daniel, Warner, Evan W., Herberts, Cameron, Ritch, Elie, Beja, Kevin, Loktionova, Yulia, Hurtado-Coll, Antonio, Fazli, Ladan, So, Alan, Black, Peter C., Nykter, Matti, Tammela, Teuvo, Chi, Kim N., Gleave, Martin E., Wyatt, Alexander W.

“…Several systemic therapeutic options exist for metastatic castrate-sensitive prostate cancer (mCSPC). Circulating tumor DNA (ctDNA) can molecularly profile…”
Get full text

Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate Cancer by Annala, Matti, Struss, Werner J, Warner, Evan W, Beja, Kevin, Vandekerkhove, Gillian, Wong, Amanda, Khalaf, Daniel, Seppälä, Irma-Liisa, So, Alan, Lo, Gregory, Aggarwal, Rahul, Small, Eric J, Nykter, Matti, Gleave, Martin E, Chi, Kim N, Wyatt, Alexander W

“…Abstract Background Germline mutations in DNA repair genes were recently reported in 8–12% of patients with metastatic castration-resistant prostate cancer…”
Get full text

The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer by Bishop, Jennifer L, Thaper, Daksh, Vahid, Sepideh, Davies, Alastair, Ketola, Kirsi, Kuruma, Hidetoshi, Jama, Randy, Nip, Ka Mun, Angeles, Arkhjamil, Johnson, Fraser, Wyatt, Alexander W, Fazli, Ladan, Gleave, Martin E, Lin, Dong, Rubin, Mark A, Collins, Colin C, Wang, Yuzhuo, Beltran, Himisha, Zoubeidi, Amina

“…Mechanisms controlling the emergence of lethal neuroendocrine prostate cancer (NEPC), especially those that are consequences of treatment-induced suppression…”
Get more information

Reproducibility and efficiency of serum-derived exosome extraction methods by Caradec, Josselin, Kharmate, Geetanjali, Hosseini-Beheshti, Elham, Adomat, Hans, Gleave, Martin, Guns, Emma

“…Exosomes are emerging as a source of biomarkers with putative prognostic and diagnostic value. However, little is known about the efficiency, reproducibility…”
Get full text

Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo by Thomas, Christian, Lamoureux, Francois, Crafter, Claire, Davies, Barry R, Beraldi, Eliana, Fazli, Ladan, Kim, Soojin, Thaper, Daksh, Gleave, Martin E, Zoubeidi, Amina

“…The progression to castration-resistant prostate cancer (CRPC) correlates with gain-of-function of the androgen receptor (AR) and activation of AKT. However,…”
Get full text

Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer by Wyatt, Alexander W, Annala, Matti, Aggarwal, Rahul, Beja, Kevin, Feng, Felix, Youngren, Jack, Foye, Adam, Lloyd, Paul, Nykter, Matti, Beer, Tomasz M, Alumkal, Joshi J, Thomas, George V, Reiter, Robert E, Rettig, Matthew B, Evans, Christopher P, Gao, Allen C, Chi, Kim N, Small, Eric J, Gleave, Martin E

“…Real-time knowledge of the somatic genome can influence management of patients with metastatic castration-resistant prostate cancer (mCRPC). While routine…”
Get full text

Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers by Zhang, Yan, Zheng, Dayong, Zhou, Ting, Song, Haiping, Hulsurkar, Mohit, Su, Ning, Liu, Ying, Wang, Zheng, Shao, Long, Ittmann, Michael, Gleave, Martin, Han, Huanxing, Xu, Feng, Liao, Wangjun, Wang, Hongbo, Li, Wenliang

“…The incidence of aggressive neuroendocrine prostate cancers (NEPC) related to androgen-deprivation therapy (ADT) is rising. NEPC is still poorly understood,…”
Get full text

Neoadjuvant Enzalutamide Prior to Prostatectomy by Montgomery, Bruce, Tretiakova, Maria S, Joshua, Anthony M, Gleave, Martin E, Fleshner, Neil, Bubley, Glenn J, Mostaghel, Elahe A, Chi, Kim N, Lin, Daniel W, Sanda, Martin, Novotny, William, Wu, Kenneth, Kantoff, Philip W, Marck, Brett T, Plymate, Stephen, Balk, Steven P, Nelson, Peter S, Matsumoto, Alvin M, Lis, Rosina T, Kibel, Adam, Haas, Gabriel P, Krivoshik, Andrew, Hannah, Alison, Taplin, Mary-Ellen

“…Prostate cancer is dependent on androgen receptor (AR) activation. Optimal AR antagonism may effectively cytoreduce local disease and suppress or eliminate…”
Get full text

Clusterin Mediates TGF-β-Induced Epithelial―Mesenchymal Transition and Metastasis via Twist1 in Prostate Cancer Cells by SHIOTA, Masaki, ZARDAN, Anousheh, TAKEUCHI, Ario, KUMANO, Masafumi, BERALDI, Eliana, NAITO, Seiji, ZOUBEIDI, Amina, GLEAVE, Martin E

“…TGF-β promotes epithelial-mesenchymal transition (EMT) and induces clusterin (CLU) expression, linking these genes to cancer metastasis. CLU is a pleiotropic…”
Get full text

Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201) by Borgmann, Hendrik, Lallous, Nada, Ozistanbullu, Deniz, Beraldi, Eliana, Paul, Naman, Dalal, Kush, Fazli, Ladan, Haferkamp, Axel, Lejeune, Pascale, Cherkasov, Artem, Gleave, Martin E.

“…Darolutamide (ODM-201) is a novel androgen receptor (AR) antagonist with a chemical structure distinctly different from currently approved AR antagonists that…”
Get full text